Sesen Bio — Corporate Update (January 2021)
82 slides from Sesen Bio's corporate update, Jan 11, 2021
Slide 1: January 2021 Business Update
NASDAQ: SESN January 2021 Business Update January 11, 2021
Slide 2: Forward-Looking Statements
2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical dev
Slide 3: January 2021 Business Update
3 JANUARY 2021 BUSINESS UPDATE 1. Differentiated MOA and clinical profile creates opportunity for Vicineum to be best-in-class therapeutic 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Significant global commercial opportunity; projected $1B - $3B peak r
Slide 4: Our Mission and the Patient Journey
O U R M I S S I O N I S TO S AV E A N D I M P ROV E T H E L I V E S O F PAT I E N T S W I T H C A N C E R BLOOD IN URINE Begin tests Cytology DIAGNOSIS BCG Testing Urologist visit UROLOGIST MAKES TREATMENT CHOICE Bladder removal See blood in urine; try different antibiotic See PCP; therapeutic trial
Slide 5: 2020: A Year of Execution Excellence
5 2020: A Year of Execution Excellence Corporate Highlights 1Q 2020 2Q 2020 3Q 2020 4Q 2020 Positive Pre-Submission meeting with EMA Completed DS PPQ campaign Favorable market research results vs. Keytruda Favorable Scientific Advice from EMA (Clinical) Received PIP waiver from EMA Signed 1st OUS de
Slide 6: Significant Unmet Need for Patients with Bladder Cancer
6 There is a Significant Unmet Need for Patients with Bladder Cancer with Limited Treatment Options Available Common Types of Cancer Estimated New Cases 2020 Estimated Deaths 2020 1. Breast Cancer (Female) 276,480 42,690 2. Lung and Bronchus Cancer 228,820 135,720 3. Prostate Cancer 191,930 33,330 4
Slide 7: Vicineum Dual Mechanism of Action
7 Vicineum has a Highly Differentiated Dual Mechanism of Action (MoA) An Important Advancement in the Category of Precision Oncology • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets
Slide 8: Vicineum Highly Differentiated Clinical Profile
8 Vicineum has a Highly Differentiated Clinical Profile *As referenced in FDA NMIBC Guidance for Industry, February 2018. Source: Phase III data as of the May 29, 2019 data cut. For additional information regarding Phase III clinical trial data please refer to slides 33-54. Efficacy Data Safety Data
Slide 9: Partnership Opportunity with LUMC
9 Partnership Opportunity with LUMC Further Supports the Targeting Specificity of Vicineum Gastric Cancer Colorectal Cancer Esophageal Cancer LUMC = Leiden University Medical Center, the university hospital affiliated with Leiden University. LUMC is a modern university medical center for research, e
Slide 10: Favorable Cost-Effectiveness Profile Based on ICER Report
10 Favorable Cost-Effectiveness Profile for Vicineum Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER) Overview: • ICER is the leading Health Technology Assessment body in the United States, and is an independent non-profit, research organization that
Slide 11: BLA Finalized and Submitted to the FDA
11 BLA Finalized and Submitted to the FDA on December 18, 2020 Positive Analytical Comparability Data Led to BLA Completion General corporate information Patent information and exclusivity Waivers Draft Label Risk management plan Draft carton and container labels 24 Non-clinical studie
Slide 12: Completion of Vicineum BLA Submission in December 2020
12 Completion of Vicineum BLA Submission in December 2020 Sources: FDA applications for oncology products 2006 – 2015. Thomas D.W. et al., Clinical development success rates 2006-2015. 2016. Bio, BioMedTracker and Amplion. Phase Probability of Approval Products at end of Phase I 5% Products at end o
Slide 13: Forward-Looking Timeline for Vicineum
13 4Q 20 1Q 21 2Q 21 3Q 21 4Q 21 2Q 221Q 22 Positive progress in the US and Europe enables a clear regulatory path forward with the following anticipated milestones: BLA completion BLA approval BLA=Biologics License Application; MAA=Marketing Authorization Application; HTA=Health Technology Assessme
Slide 14: Potential for Peak Revenue of $1B - $3B Globally
14 • Substantial US opportunity and OUS potential of roughly two times the US • Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after approval and launch • Compelling intent to prescribe research in the US • Highly con
Slide 15: Key Partnership with Hikma in MENA
15 Key partnership with leading partner in MENA Hikma Pharmaceuticals Profile • Multi-national pharma company specializing in the development and commercialization of a broad range of high-quality medicines across the US, the MENA and Europe • Public company headquartered in London with a market cap
Slide 16: Milestones Achieved through Qilu Partnership
16 Significant Milestones Achieved through Qilu Pharmaceutical Partnership Overview of Key Progress • $12M upfront received on September 29, 2020 • CMO framework agreement signed on December 4, 2020 • Helps to ensure reliable global supply and creates opportunity for a reduction in COGS • $3M milest
Slide 17: OUS Opportunity Roughly Double the US
17 We Estimate the OUS Opportunity for Vicineum is Roughly Double the US Geography Peak Year Revenue Opportunity for Vicineum (captures 80% of variance) Europe $450M - $1,125M United States* $423M - $942M MENA $158M - $420M China $155M - $418M Rest of Asia (incl. Japan) $109M - $282M Latin America $
Slide 18: 2020 Financial Highlights
18 2020 Financial Highlights Strengthening the Balance Sheet while Minimizing Dilution YE 2019 YE 2020 % Change Cash, cash equivalents and restricted cash $48M $55M1 +15% Stock price $1.04 $1.35 +30% Market cap $111M $190M +71% 1Amount is preliminary, has not been audited and is subject to change up
Slide 19: Sesen Bio Highlights
19 SESEN B IO HIGHLIGHTS 1. Differentiated MOA and clinical profile creates opportunity for Vicineum to be best-in-class therapeutic 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Significant global commercial opportunity; projected $1B - $3B peak revenue
Slide 20: Thank You
THANK YOU
Slide 21: Talented and Experienced Leadership Team
21 Thomas Cannell, DVM President, CEO and Director Glen MacDonald, Ph.D. Chief Technology Officer Mark Sullivan General Counsel and Corporate Secretary Erin Clark Vice President, Corporate Strategy and Investor Relations Monica Forbes Chief Financial Officer Omar Rifi Vice President, Business Develo
Slide 22: Appendix - Table of Contents
22 Appendix - Table of Contents Section Slide number Unmet Medical Need 23-26 Dual Mechanism of Action 27-29 Regulatory 30-32 Clinical Data 33-54 Commercial Opportunity 55-74 Manufacturing & Supply Chain 75-80 Intellectual Property 81-82 For Investor Purposes Only
Slide 23: Unmet Medical Need
23 Unmet Medical Need Appendix
Slide 24: Significant Unmet Medical Need in NMIBC
24 BCG ~440,000 new cases each year globally1 is complicating patient care Significant Unmet Medical Need in NMIBC 1Bray F et al. CA Cancer J Clin, 2018. 2Anastasiadis et al. Therapeutic Advances in Urology, 2012. 3Siegel et al. CA Cancer J Clin, 2019. 4Svatek RS, et al. Eur Oncol. 2014. 5Office of
Slide 25: Vicineum Is Bladder-Sparing by Delaying or Avoiding Cystectomy
25 Our Phase III data suggests Vicineum is bladder-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery Self-controlled storage organ in the body Holds urine for release so the body is not exposed to harm
Slide 26: NMIBC Therapeutics Plagued by Manufacturing Issues
26 NMIBC Therapeutics Have Been Plagued by Manufacturing Issues 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production of BCG Connaught strain during facility renovations Merck announces shortages of BCG Tice strain Sanofi discontinues all global production of BCG Connaught strain M
Slide 27: Dual Mechanism of Action
27 Dual Mechanism of Action Appendix
Slide 28: Vicineum Has a Highly Differentiated Mechanism of Action
28 T cells recognize neoantigen and kill cancer cells T cell proliferation DAMPs Neoantigen release Vicineum causes immunogenic cell death by triggering damage-associated molecular patterns (DAMPs) Vicineum selectively targets EpCAM on cancer cells while generally leaving healthy cells alone Vicineu
Slide 29: Evidence of Immune System Activation
29 A f t e r 4 w k s o n t r e a t m e n t P r e - t r e a t m e n t PAT I E N T A : PAT I E N T B : Injected Tumor Injected Tumor Non-Injected Tumor Pre-clinical and Phase I Trial in SCCHN shows evidence of activation of patients’ immune systems Clinical Evidence (as seen in Phase I) Pre-Clinical E
Slide 30: Regulatory
30 Regulatory Appendix
Slide 31: FDA Guidance for BCG-Unresponsive NMIBC
31Source: FDA Guidance: BCG-Unresponsive Non-muscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry, February 2018. CRR, Complete Response Rate; DoR, Duration of Response; BCG, bacillus Calmette-Guérin; WHO, World Health Organization. 31 • Conduct nonclini
Slide 32: Positive Interactions with EMA on Regulatory Pathway
32 Positive Interactions with EMA on Regulatory Pathway for Vicineum May 7, 2020 CHMP clinical advice for Vicineum: • The nonclinical and clinical pharmacology studies, and safety database are all sufficient to support a MAA submission for Vicineum and no additional clinical trials were requested •
Slide 33: Clinical Data
33 Clinical Data Appendix
Slide 34: Strong Benefit-Risk Profile in Phase III Trial
34 : Vicineum demonstrates a strong benefit-risk profile in our Phase III Trial Benefit Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkpoint inhibitors No dose or age-related increase in AEs Intrav
Slide 35: Phase III Trial: Patient Demographics
35 Phase III Trial: Patient Demographics TURBT: transurethral resection of bladder tumor Note: Data are as of May 29, 2019 data cut CHARACTERISTICS COHORT 1 COHORT 2 COHORT 3 CIS that was refractory or recurred within 6 months of adequate BCG CIS that recurred >6 months but ≤11 months of adequate BC
Slide 36: Compelling Clinical Data Set
36 Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) Primary Endpoint CIS patients Defined as the proportion of patients who show no evidence of high-risk disease, or disease progression (e.g., T2 or more advanced disease). • 40% CRR at 3 months • Lo
Slide 37: Complete and Partial Response in Phase II
37 Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response Start of Treatment with Vicineum 3-Month Response 40% of patients had a complete response 43% of patients had a partial response 17% of patients had no response *Note: Data are from P
Slide 38: Duration of Response
38 Duration of response: defined as the time of complete response to treatment failure. *Not Estimable, the upper bound for the 95% confidence interval has not reached the median. **Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Median duration of response for th
Slide 39: Duration of Response by BCG Exposure
39 Duration of Response: Vicineum is generally more efficacious in CIS patients treated with less BCG Duration of response: defined as the time of complete response to treatment failure. *Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. The BCG shortage may cause a
Slide 40: Longer Complete Response Raises Probability of Remaining Cancer-Free
40Duration of response: defined as the time from complete response to treatment failure. *Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free 17% 42% 56% 61% 7
Slide 41: Time to Disease Recurrence
41 Time to Disease Recurrence: Time to Disease Recurrence: 50% of high-risk papillary patients who were treated with Vicineum are disease-free at 1 year Time to disease recurrence: defined as the time from the date of the first dose of study treatment to treatment failure. Median time to disease rec
Slide 42: Time to Cystectomy Data
42 2018 FDA Guidance: The goal of therapy in patients with BCG-unresponsive NMIBC is to avoid cystectomy. % o f P at ie nt s C ys te ct o m y- Fr ee Median 3 6 9 12 15 18 21 240 27 30 33 Time from start of treatment (months) KM Estimate Censored 95% CI X Legend: No patient on treatment progressed to
Slide 43: Time to Cystectomy: Responders
43 Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment Time to cystectomy: defined as the time from the date of first dose of study treatment to surgical bladder removal. Data consist of patients from all cohorts (n=133). % o f P at ie
Slide 44: Overall Survival
44 Overall Survival 1- and 2-year survival rates of patients on trial are comparable to those of the general population of similar age and gender demographics (predominantly male in their 70s) 1U.S. Social Security Administration Actuarial Life Table (https://www.ssa.gov/oact/STATS/table4c6.html), B
Slide 45: Additional Vicineum Clinical Data: Phase II vs. Phase III
45 Additional Vicineum Clinical Data Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-months 18% (8%-32%) 21%
Slide 46: Evaluable Patient Data Tables by Cohort
46 Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 1
Slide 47: Recurrence-Free Rate in Papillary Patients
47 Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free (RF) Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-month
Slide 48: Safety and Tolerability
48 Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Category Phase II Patients (%) Phase III Patients (%) Any AE 43 (94%) 117 (88%) Grade 3-5 AEs 9 (20%) 29 (22%) Treatment-related AEs 30 (65%) 66 (50%) Treatment-related Grade 3-5
Slide 49: No Age-Related Increase in Adverse Events
49 M ea n A E s/ pa tie nt 0 2 4 6 8 10 Safety and Tolerability: No age-related increase in adverse events in our Phase III trial Note: Data consist of patients from all cohorts (n=133). Mean AEs for all patients: 8.1 (range 0-54), Mean treatment-related AEs for all patients: 2.2 (range 0-51). Adver
Slide 50: Confidence Interval Above FDA Success Criterion
50 Vicineum confidence interval above FDA success criterion based upon complete response of other agents in patients with Carcinoma in situ Please use caution when drawing comparisons across different clinical trials 2Data are as of May 29, 2019 data cut from the Phase III VISTA trial 3To demonstrat
Slide 51: Overview of Planned Confirmatory Trial
51 High-Level Overview of Planned Confirmatory Trial Successful in alignment with the FDA on the design of the post-marketing confirmatory trial for Vicineum Key Elements The confirmatory trial will enroll BCG-refractory patients who received less-than-adequate BCG* • This represents a broader patie
Slide 52: Head and Neck Cancer: Difficult-to-Treat
HEAD AND NECK CANCER: Difficult-to-Treat & Dominated by Primary Tumor • Head and neck cancer affects >650,000 people worldwide; ~350,000 deaths each year1 • 90% are squamous cell carcinomas of the head and neck (SCCHN)1 - Two-thirds diagnosed with advanced disease and severe prognosis • High risk of
Slide 53: Vicineum Monotherapy Studies in Late-Stage SCCHN
53 PHASE 1 TRIALS ASSESSING DAILY AND WEEKLY DOSES SUGGEST IMMUNE-DRIVEN RESPONSE • Anti-tumor activity of 43% on daily dose; 62% on weekly dose • Observed regression or complete resolution of non- injected tumors • 207 days mean overall survival for EpCAM-positive patients vs. 125 days for EpCAM-ne
Slide 54: Pipeline of Targeted Therapies
54 Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicineum in combination with checkpoint inhibitors. Vicineum in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 trial run by the National Cancer Institute. We have d
Slide 55: Commercial Opportunity
55 Commercial Opportunity Appendix
Slide 56: Virtuous Cycle Across Physicians, Patients and Payers
56 Virtuous Cycle: High possibility that all three key segments are advocates & take action Sources: Sesen Bio internal market research: Patient Journey Insights, Blue Print qualitative study May 2018, n=24; Sesen Market Opportunity, Monitor Deloitte qualitative and quantitative (n=34) study October
Slide 57: Differentiated vs. Branded Agents in Urology
57 Brand Logo Differentiated vs. branded agents in Urology TM
Slide 58: Continuity of Care for Patients with NMIBC
58 Treatment Protocol BCG Vicineum Checkpoint Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X Vicineum has the Potential to Provide Continuity of Care for Patients with NM
Slide 59: Clinical Data from Emerging Treatments for NMIBC
59 Gen Vicineum Profile (Phase III Data) Keytruda Profile (Phase II Data) Tecentriq Profile (Phase II Data) Efficacy N=89 N=102 N=73 Complete Response Rate • At 3 Months • At 12 Months • At 18 Months 40% (CI: 30-51) 17% 15% 41% (CI: 32-51) 20% 13% 41% (CI: 30-53) No data reported No data reported Ti
Slide 60: 2020 Market Research Results
60 5.4 8.2 8.2 8.6 5.2 6.2 3.4 5.8 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Efficacy Safety Ease of integration Interest in use of product A ve ra ge R at in g Vicineum Profile Keytruda Profile 2020 Market Research Results High Prescribing Urologists Prefer Vicineum Profile Source: Emerging trea
Slide 61: Reasons Urologists Prefer Vicineum Profile
61 1Q 2020 Market Research Results Reasons Urologists Prefer Vicineum Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perc
Slide 62: Highly Concentrated Prescriber Base
62 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 20 0 40 0 60 0 80 0 1, 00 0 1, 20 0 1, 40 0 1, 60 0 1, 80 0 2, 00 0 2, 20 0 2, 40 0 2, 60 0 2, 80 0 3, 00 0 3, 20 0 3, 40 0 3, 60 0 3, 80 0 4, 00 0 4, 20 0 4, 40 0 4, 60 0 4, 80 0 BCG Prescribers Highly Concentrated Prescriber Base Allows for Efficien
Slide 63: Caregiver Education via Digital and Social Channels
63 At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital • Paid search • Organic search • Videos • Banners • Website (branded or unbranded) Social • Facebook community groups •
Slide 64: Pricing and Reimbursement
64 Pricing and Reimbursement US Benchmarks Price Reference (Annual Cost) $200K $0K Sources: 1Center for Medicare and Medicaid Services (CMS) Average Selling Price (ASP) Price List as of 1Q 2020 (cms.gov). 2Payer Interviews, ClearView Analysis, n=10, March 2019. *Note: Payers cited a possibility of u
Slide 65: Competitive Scan
65 Checkpoint Inhibitors: Keytruda • Approved for NMIBC January 2020 • Reimbursed at $175,000/year with minimal payer restrictions Tecentriq • Awaiting Phase III enrollment • Phase II closed prematurely as it failed to meet futility endpoint Gene Therapy: Adenovirus Vectors Adstiladrin • Missed May
Slide 66: Competitive Summary: BCG-Unresponsive NMIBC Therapies
66 Competitive Summary: BCG-Unresponsive NMIBC therapies Description Report CR rate at discrete timepoints Patient failures taken off therapy Local and Central review of pathology BCG + N-803 BCG in combo with rIL-15 Vicineum Fusion Protein (Dual MOA) Keytruda Checkpoint Inhibitor Adstiladrin Gene
Slide 67: Sesen Bio OUS Strategy Overview
67 Sesen Bio OUS Strategy Overview • Vicineum is a product with potential for registration and reimbursement in multiple developed markets • OUS opportunity for Vicineum is 2-3 times larger than the US • Efficient process to manage strong, engaged relationships with key partners worldwide • Partner
Slide 68: Sesen Bio OUS Update
68 Sesen Bio OUS Update July 31, 2020: Announced partnership with Qilu Pharmaceutical for the manufacture, development and commercialization of Vicineum in Greater China* • Represents the first of 6-10 anticipated OUS deals • Financial terms include significant sources of non-dilutive capital • Qilu
Slide 69: Partnership Opportunity in China: Qilu Pharmaceutical
69 Partnership Opportunity in China: Qilu Pharmaceutical Profile • Top 10 Pharmaceutical Company in China with >$3B in annual revenue • Extensive clinical experience • 2nd largest clinical team in Chinese Big Pharma • Focused on biosimilar and innovative drugs, with nearly 40 years of clinical devel
Slide 70: Overview of Qilu License Agreement
70 Overview of Qilu License Agreement • Financial terms include significant sources of non-dilutive capital • Upfront payment of $12M in cash • Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to 12% royalties on net sales for at least 12 years • Qilu will be
Slide 71: Building Our Reputation as a Partner of Choice
71 Strong cultural fit between Sesen and Qilu Significant CMC capabilities and experience Highly knowledgeable clinical and manufacturing teams Vicineum is a highly differentiated product that addresses a huge unmet need Building Our Reputation as a Partner of Choice Feedback Received from Qilu Duri
Slide 72: Forecast Simulation Model Key Assumptions
72 Forecast Simulation Model Key Assumptions US and OUS High-risk NMIBC patients unresponsive to BCG Estimated peak market share Approximate year 1 doses received Anticipated annual CMS ASP Prevalence (relative to US) Price (relative to US) US Inputs OUS Inputs Output Peak Revenue Opportunity for Vi
Slide 73: Simulation Inputs: US Market
73 Simulation Inputs: US Market Estimated patients eligible for branded therapy1 (Annual high-risk NMIBC patients unresponsive to BCG) Lower Bound 7,800 patients Upper Bound 20,400 patients Estimated peak market share2 (Likely share of branded agents) Approximate year 1 doses received3 (Percent of p
Slide 74: Simulation Inputs: OUS Market
74 Simulation Inputs: OUS Market Sources: Ferlay. Intern. J. Canc. 2015; UN World Population Reports; SEER; GLOBOCAN; RedBook; Lauertaxe; Ameli; NICE; Vademecum; AIFA; NHI; CADTH; ANVISA; CBiP; Danish Medicines Agency; The Pharmaceutical Benefits Scheme; Saudi Food & Drug Authority; South African Me
Slide 75: Manufacturing & Supply Chain
75 Manufacturing & Supply Chain Appendix
Slide 76: Vicineum End-to-End Supply Chain
76 Vicineum End-to-End Supply Chain World-class manufacturing and distribution capabilities ensure execution excellence • Vicineum Drug Substance manufacturer • 7 commercial products launched from site where Vicineum is manufactured o 3 produced via E. coli o 2 oncology products • 30+ years manufact
Slide 77: Highly Reliable Manufacturing Process for Vicineum
77 Highly Reliable Manufacturing Process for Vicineum Cell Bank 2000 L E. coli Production Bioreactor 5: Q-Sepharose HP 5 Column Purification Shake flask Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) DP Fill Finish (7 mL @ 5mg/mL)1: Q-Se
Slide 78: Reliable and Inexpensive Manufacturing Process
78 Reliable and Inexpensive Manufacturing Process • Vicineum is manufactured using a robust, industry-standard microbial expression system • The manufacturing process is highly reliable, reducing the risk of supply shortages • The manufacturing process is inexpensive, leading to a relatively low cos
Slide 79: Commercial Manufacturing Strategy Based on Comparability
79 Commercial Manufacturing Strategy Based on Demonstrating Comparability The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing • Assesses the purity, biological activity and general characteristics of Vicineum 2. Biophysical Characterization • Assesses the
Slide 80: Meaningful Progress on Demonstrating Comparability
80 Meaningful Progress on Demonstrating Comparability Indicates acceptance criteria met for batches used in clinical trials (Sesen) or technology transfer (FUJIFILM Diosynth Biotechnologies) Sesen FUJIFILM Diosynth Biotechnologies Test Phase III PPQ1 PPQ2 PPQ3 Appearance pH Identity
Slide 81: Intellectual Property
81 Intellectual Property Appendix
Slide 82: Potential for Years of Biologics Marketing Exclusivity
82 Potential for 12 years of biologics marketing exclusivity from date (TBD) of first approval* Stabilized Chimeric Immunoglobulins (April 2020 - July 2020) 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Methods of Treating Cancer Using an Immunotoxin (April 202